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E-mail address: gareth.john@mssm.edu (G.R. JohnMultiple sclerosis (MS) is an inﬂammatory demyelinating disease of the CNS. Conduction block in
demyelinated axons underlies early neurological symptoms, but axonal transection and neuronal
loss are believed to be responsible for more permanent chronic deﬁcits. Several therapies are
approved for treatment of relapsing-remitting MS, all of which are immunoregulatory and clinically
proven to reduce the rate of lesion formation and exacerbation. However, existing approaches are
only partially effective in preventing the onset of disability in MS patients, and novel treatments
to protect myelin-producing oligodendrocytes and enhance myelin repair may improve long-term
outcomes. Studies in vivo in genetically modiﬁed mice have assisted in the characterization of
mechanisms underlying the generation of neuropathology in MS patients, and have identiﬁed
potential avenues for oligodendrocyte protection and myelin repair. However, no treatments are
yet approved that target these areas directly, and in addition, the relationship between demyelina-
tion and axonal transection in the lesions of the disease remains unclear. Here, we review transla-
tional research targeting oligodendrocyte protection and myelin repair in models of autoimmune
demyelination, and their potential relevance as therapies in MS.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction rate of axonal transection and neuronal loss. Moreover, such ap-Multiple sclerosis (MS) presents in its initial form most com-
monly in young adults, especially women [1]. Conduction block in
demyelinated axons is understood to be responsible for early neuro-
logical deﬁcits [1], while axonal transection and neuronal loss
underlie more permanent later disability [2]. Endogenous myelin
repair is known to exist in early lesions, and leads to return of con-
duction and function [3,4], but this process gradually fails as the dis-
ease progresses [5,6]. For CNS remyelination to occur, progenitors of
myelin-forming oligodendrocytes must be recruited into demyeli-
nated areas, and then subsequently differentiate into mature, mye-
linating cells which each typically wrap multiple axons [7–9].
Consistentwith thismodel, committedoligodendrocyte progenitors
(OPCs) have been detected in developing brain, normal adult human
brain,MS lesions and animalmodels [5,10–12]. Studies suggest that
approaches protective for oligodendrocytes and that enhance mye-
lin repair are likely to improve long-term outcomes and reduce thechemical Societies. Published by E
kinson Center for MS, Mount
York, NY 10029, USA. Fax: +1
).proaches could be employed in combination with currently avail-
able immunoregulatory treatments, for additive or synergistic
effects [13]. However, all therapies currently approved for the treat-
ment of relapsing-remitting MS are immunoregulatory, and do not
directly address oligodendrocyte protection and remyelination.
These areas are thus the subject of intense current research focus.
The ﬁrst neuroprotectant approved for use in MS will represent a
signiﬁcant advance in theﬁeld, andmay also have far-ranging impli-
cations for the treatment of other neurodegenerative disorders.
Studies in knockout mice and conditional mutants have acceler-
ated our understanding of lesion pathogenesis in MS models, and
have revealed pathways controlling oligodendrocyte survival and
myelin repair [14]. Factors implicated in protection of oligodendro-
cytes or remyelination include neurotrophins, gp130 neurotrophic
cytokines, insulin-like growth factors, and retinoid receptor signal-
ing. By contrast, pathways shown to restrict repair have included
LINGO-1, bone morphogenetic proteins, and canonical Wnt and
Notch signaling [13–15] (Fig. 1). However, despite these advances,
no therapies have yet been approved that target these areas in MS
patients. Moreover, the relationship between demyelination and
axonal transection remains unclear, as does the potential for
remyelination to restrict neuronal loss in MS lesions.lsevier B.V. All rights reserved.
Fig. 1. Regulation of oligodendrocyte progenitor mitosis, differentiation and apoptosis. An outline of the progression of oligodendrocyte differentiation, from neural
progenitor (left), through speciﬁed oligodendrocyte progenitor, to mature postmitotic oligodendrocyte capable of myelin formation (right). Mechanisms of action are shown
of factors that augment (lower panel, blue/green) or restrict (upper panel, red) the number of mature myelinating cells. Retinoid X receptor signaling and the gp130 cytokines
CNTF, IL-11 and LIF promote oligodendrocyte maturation (lower panel). The gp130 cytokines also improve the viability of mature oligodendrocytes or their precursors, a
property they share with the insulin-like growth factors IGF-1 and IGF-2, and the neurotrophin, NT-3. Additionally, NT-3 potentiates precursor proliferation. At later stages of
maturation, neuregulin 1 type III-ErbB signaling facilitates axonal ensheathment and myelin wrapping. Conversely, bone morphogenetic proteins inhibit oligodendrocyte
lineage speciﬁcation and subsequent progenitor differentiation (upper panel). Canonical Notch and Wnt signaling restrict maturation, and maintain the size of the progenitor
pool.
3814 J. Zhang et al. / FEBS Letters 585 (2011) 3813–3820Here, we review potential approaches for oligodendrocyte pro-
tection and remyelination in MS and its animal models. Obstacles
to development of novel therapies in these areas will also be
discussed.
2. Pathways promoting oligodendrocyte viability, maturation
and myelination
2.1. Gp130 neurotrophic cytokines
Gp130 was originally identiﬁed as a signal transducing compo-
nent that associated with the interleukin 6 receptor (IL-6R) follow-
ing ligand binding [16]. However, subsequent work deﬁned gp130
as a receptor shared by all members of a large pleiotropic family of
cytokines. The family includes IL-6, IL-11, IL-27, oncostatin M
(OSM), leukemia inhibitory factor (LIF), cardiotrophin 1(CT-1),
and ciliary neurotrophic factor (CNTF) [17]. IL-6R and IL-11Ra in-
duce gp130 homodimerization [18], whereas LIF, CNTF, oncostatin
M and CT-1 binding lead to heterodimerization with the LIF recep-
tor (LIFR) [19]. Either homo- or heterodimerization triggers the
activation of Janus kinase (JAK) tyrosine kinases [20,21], which
leads to cytokine- and cell type-speciﬁc phosphorylation and nu-
clear translocation of Stat transcription factors [22]. Stat-indepen-
dent signaling has also been described [22].
Members of the gp130 cytokine family play important roles in
the immune, hemopoietic, cardiovascular and reproductive system
[22]. Importantly, the family has also demonstrated strong trophic
functions within the CNS, notably neuroprotection. For example,
mice deﬁcient in CNTF or CNTFR, and CT-1/ mice, display loss
of motoneurons [23,24], and CNTF is protective in neurodegenera-
tive models in primates [25]. These reports have understandably
stimulated research examining mechanisms underlying these
effects, and the translational potential of gp130 signaling in CNS
disease. Relevant to this review, investigation of effects on oligo-
dendrocytes has focused primarily on CNTF, LIF and IL-11.
2.1.1. Neuroprotective roles of CNTF and LIF
CNTF promotes the ﬁnal maturation of oligodendrocyte progen-
itors, and via gp130 and Jak signaling [26] leading to activation ofSTAT-1 and STAT-3 [27]. Soluble interleukin-6 (IL-6) receptor/IL-6
fusion protein similarly induces STAT1/3 phosphorylation and en-
hances differentiation of rodent oligodendrocyte progenitor cul-
tures in vitro [28]. CNTF and LIF also promote oligodendrocyte
survival [29,30]. CNTF/ or LIFR+/gp130+/ mice with the MS
model, experimental autoimmune encephalomyelitis (EAE), dis-
play exacerbated disease and increased oligodendrocyte apoptosis,
although LIF/mice also show an attenuated late phase of disease
[31–33]. Administration of CNTF is not sufﬁcient to promote oligo-
dendrocyte remyelination in demyelinating lesions induced by
microinjection of ethidium bromide in vivo [34], although trans-
plantation of adult oligodendrocyte precursor cells expressing
CNTF has been reported to promote remyelination and functional
recovery following traumatic injury to the spinal cord [35]. More-
over, CNTF administration does protect mice from inﬂammatory
pathology in EAE for the duration of treatment [36]. Endogenous
LIF protects mature oligodendrocytes from demyelination and also
enhances remyelination, and exogenous LIF has also been used
successfully to limit the consequences of oligodendrocyte damage.
[37,38].
Taken together, these ﬁndings implicate CNTF and LIF signaling
as potential neuroprotective and pro-regenerative approaches for
therapy of MS and other demyelinating diseases. However, despite
successes of CNTF in studies in animal models of neurodegenera-
tion [25,39], testing in neurodegenerative conditions in human pa-
tients was unsuccessful in [40,41], and these failures have
signiﬁcantly dampened enthusiasm for clinical trials in MS. Inter-
estingly, however, the reasons for the ineffectiveness of CNTF in
human trials have not been fully investigated, and it remains
possible that lack of access to the CNS parenchyma through the
blood-brain barrier may be responsible in part or whole for these
negative ﬁndings.
2.1.2. IL-11 – oligodendrocyte protection and immunoregulation
Experiments in primary human cultures and mathematical
modeling in rodent oligodendrocyte progenitors have shown that
IL-11 enhances oligodendrocyte survival and maturation, and that
these effects may be more potent than those of LIF [42–44] (Fig. 1).
IL-11 treatment is also associated with increased myelin formation
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predominantly to improved survival of oligodendrocyte lineage
cells [44]. Interestingly, in contrast to the predominantly neuro-
protective effects of CNTF and LIF, IL-11 displays signiﬁcant immu-
noregulatory actions. Studies in vivo have shown that
administration of recombinant IL-11 decreases the clinical course
and neuropathology of EAE, whereas IL-11Ra/ mice display in-
creased demyelination and oligodendrocyte loss, and delayed
remyelination, accompanied by exacerbated CNS inﬂammation
[42,44]. While IL-11 directly increases the viability of oligodendro-
cyte lineage cells, its immunoregulatory properties depend on pro-
apoptotic actions on antigen-presenting dendritic cells (DCs)
[42,44]. Interestingly, both effects are dependent on lineage-
speciﬁc activity of the transcription factors Stat1 versus Stat3. In
both cell types, Stat3 is anti-apoptotic, whereas Stat1 promotes cell
death. However, following IL-11 treatment, activity of Stat3
predominates over its relative in oligodendrocytes, whereas the
pro-apoptotic effects of Stat1 prevail in DCs [44]. Collectively, these
data reveal novel mechanisms underlying the actions of a neuro-
protective and immunoregulatory member of the gp130 cytokine
family in inﬂammatory demyelinating disease, and suggest new
avenues to enhance oligodendrocyte survival and restrict CNS
inﬂammation in MS.
2.2. Insulin-like growth factors (IGFs)
IGFs are neuroprotective trophic factors for cells of the oligo-
dendrocyte lineage [45], which encompass IGF-1 and IGF-2, and
the regulatory IGF-binding proteins (IGFBPs). IGF-1 and IGF-2 sig-
nal through the IGF-1 receptor (IGF-1R) and IGF-2 receptor (IGF-
2R), respectively. Interestingly, IGF-1 is expressed at high level in
neuron-rich areas of the brain, whereas IGF-2 is found at high lev-
els in myelinated tracts, and is the most abundant IGF in the CNS
[46].
The phenotypes of mutants for the IGFs and their binding pro-
teins have provided important insights into the roles of members
of the family in CNS development. For example, mice deﬁcient
for IGF-1 display reduced brain size, hypomyelination, reduced oli-
godendrocyte numbers and severe neuronal loss [47]. IGF-1 exerts
neurotrophic and neuroprotective effects in vitro, and enhances
neuronal survival and differentiation. By comparison, the brains
of transgenic mice overexpressing IGF-1 are 55% larger than con-
trols, and show increased cell number and size, and myelin content
in these mice is increased by 130% [48]. Moreover, the percentage
of myelinated axons and myelin thickness are reduced in trans-
genic animals overexpressing IGFBP-1, [49]. IGF-1 enhances oligo-
dendrocyte survival and supports differentiation in vitro, which is
accompanied by enhanced process branching and increased pro-
duction of myelin proteins [45,50].
Suggesting relevance to de- and remyelination, injection of
IGF-1 into animals with EAE reduces the numbers and area of
demyelinating lesions [51]. IGF-1 therapy has also been reported
to increase the number of axons containing regenerating myelin
segments, reduce blood–spinal cord barrier permeability, and
enhance myelin gene expression, and these changes have been
shown to be associated with rapid clinical and pathological recov-
ery in the treated animals. However, although subsequent studies
in chronic relapsing EAE have shown transient clinical ameliora-
tion and low-level remyelination after IGF-1 administration during
the acute phase of disease, samples from acute phase-treated ani-
mals did not show potentiated remyelination at chronic time
points [52].
The translational potential of IGF-1 also remains unfulﬁlled in
MS. In active lesions from MS patients, IGF-1 expression localizes
to reactive astrocytes, while IGF-2 is expressed by activated
microglia [53]. However, a clinical trial examining the conse-quences of recombinant IGF-1 therapy in MS patients failed to pro-
duce statistically signiﬁcant ﬁndings [54]. Similar to trials using
CNTF, the extent to which this result was attributable to inability
of IGF-1 to cross the BBB is unclear [54]. Restrictions in CNS access
and issues with cell type speciﬁcity may once again represent a
confound in clinical trial design in the case of IGF-1, confusing
interpretation for another potentially neuroprotective and regen-
erative therapeutic pathway in MS.
2.3. Neurotrophins
The neurotrophins (NTs) are a family of soluble mediators that
include nerve growth factor (NGF), brain-derived neurotrophic fac-
tor (BDNF), neurotophin-3 (NT-3) and neurotophin-4/5 (NT-4/5)
[55]. Members of the family interact with two classes of trans-
membrane receptors: the receptor tyrosine kinase tropomyosin-
related kinases (Trk), and the TNF-a receptor superfamily p75
neurotrophin receptor p75NTR [56]. Each neurotrophin displays
selective high-afﬁnity interaction with speciﬁc Trk receptors, with
NGF binding to TrkA, BDNF and NT-4/5 to Trk-B, and NT-3 to Trk-C.
All bind additionally to p75NTR. The precursor form of NTs are
known as proneurotrophins, and these are also found in abundance
in the brain, and are believed to be biologically active [57,58].
Neurotrophins were originally characterized as playing impor-
tant roles in the development and maturation of speciﬁc popula-
tions of CNS neurons [56]. However, they have also been found
to exert strong effects on myelinating glia and on earlier uncom-
mitted progenitors, and these will be summarized here, together
with their translational potential.
2.3.1. Neurotrophins and myelination
Studies have revealed NGF as regulating myelination of TrkA-
expressing dorsal root ganglion (DRG) neurons by both Schwann
cells and oligodendrocytes in vitro, and have demonstrated that
these effects are mediated via direct interaction between NGF
and neuronal TrkA receptors [59]. However, the interaction be-
tween NGF and TrkA leads to differential outcomes in the two
co-culture types, promoting myelin formation by Schwann cells
but inhibiting oligodendrocyte myelination [59]. Thus, the impact
of NGF on myelin formation includes important effects on neurons.
However, additional investigations have shown that NGF also en-
hances oligodendrocyte survival, although it does not promote
OPC proliferation unless coadministered with the mitogen ﬁbro-
blast growth factor [60].
Unlike NGF, the impact of NT-3 on myelin formation encom-
passes potent glial effects. An important role in promoting myeli-
nation is supported by the phenotype of NT-3 or TrkC-deﬁcient
mutants. NT-3 is essential for cardiovascular development and so
most NT3/mice die within 3 weeks of birth [61], but at postnatal
day 0 (P0) mice of this genotype exhibit a 35% reduction in the
number of OPCs in the ventral spinal cord [62]. In addition, quan-
tiﬁcation of more mature oligodendrocyte lineage cells reveals
signiﬁcant reductions in the number of differentiated GalC+ oligo-
dendrocytes (28% reduction) and myelin basic protein (MBP)
mRNA+ (27% reduction) cells in spinal cords of NT-3–/– animals
[62]. TrkC/ mutants display comparable ﬁndings [62]. Experi-
ments in vitro have described the effects of NT-3 on oligodendro-
cyte survival and proliferation, in addition to promoting the
clonal expansion of oligodendrocyte progenitor cells when com-
bined with the mitogen platelet-derived growth factor [29,63]
(Fig. 1). In addition, NT-3 has been shown to enhance myelination
in co-cultures of OPCs and neurons, by inducing differentiation of
OPCs into myelin-forming cells [64], and NT-3-transfected OPCs
show increased MBP expression and enhanced myelination of hip-
pocampal neurons [65]. In the optic nerve, neutralization of NT-3
by injection of hybridoma cells secreting anti-NT-3 antibody
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oligodendrocytes [63].
Interestingly, while NGF, NT-3 and BDNF have all been shown to
promote differentiation of basal forebrain oligodendrocytes, only
NGF and NT-3 promote maturation of cortical oligodendrocytes
[66]. Whereas studies suggest relevance of BDNF in regulating
myelination in vivo, the underlying mechanism is incompletely
characterized. Most BDNF/ mice show perinatal lethality, but a
minority live for up to 21 days [67], and at P13 numbers of retinal
ganglion cells and the thickness of the retina are normal in these
survivors, but the proportion of myelinated axons in the optic
nerve is reduced, by approximately 50% [67]. This reduction is
maintained at P21, but is accompanied at this timepoint by a
reduction in optic nerve axon diameter, suggesting that BDNF–/–
mice may develop with a greater proportion of small unmyelinated
axons. Moreover, the hippocampus and cortex of BDNF/ mice
display reduced levels of MBP and PLP mRNA [68]. However, since
the phenotype of these mice combines alterations in both neuronal
and glial compartments, it is not yet clear whether these events are
mediated by BDNF acting directly on oligodendrocytes, or indi-
rectly, via effects on neuronal TrkB receptors.
2.3.2. Translational potential of neurotrophins
Translational studies have explored the potential of neurotro-
phins to establish functional recovery following nerve injury and
demyelination. Experiments in which ﬁbroblasts expressing either
BDNF or NT-3 have been transplanted into rodent spinal cords after
injury have resulted in enhanced axonal growth, OPC proliferation
and myelin formation [69]. Moreover, transplantation of Schwann
cells expressing BDNF or NT-3 into demyelinated spinal cords leads
to increased OPC proliferation and differentiation, remyelination
and locomotor recovery in mice [70]. Interestingly, studies have
also implied a functional role for BDNF in promoting axonal protec-
tion in autoimmune demyelination [71]. Remyelination and
functional recovery have also been demonstrated following trans-
plantation of glial-restricted precursor cells (GRPs) expressing a
multi-neurotrophin of BDNF and NT-3 into the CNS of rats sub-
jected to spinal cord injury [72]. However, although these reports
have provided evidence that neurotrophins are effective at pro-
moting spinal cord regeneration, the contributions of effects on
neurons versus glia to these outcomes are not yet fully established.
2.4. Neuregulin 1 type III
Members of the neuregulin 1 (NRG1) family play important
roles in development and maintenance of the central and periphe-
ral nervous systems [73]. They are ligands for Erb receptor tyrosine
kinases located on glial cells, and more than 16 isoforms are
known, encoded through multiple promoter utilization and alter-
native splicing [73,74]. These include neu differentiation factor
(NDF), heregulin, acetylcholine receptor inducing activity (ARIA),
and glial growth factor (GGF). All members of the family share a
unique epidermal growth factor (EGF)-like domain, required for
receptor activation.
The best understood function of NRG1 is in control of peripheral
myelination, where axonal NRG1 is essential for neuronal survival,
and for viability, proliferation and differentiation of myelinating
Schwann cells [75]. In the developing PNS, a threshold level of ax-
onal NRG1 type III expression is required to induce Schwann cell
ensheathment [76], and both Schwann cell proliferation and
myelination require glial ErbB2 receptors [77]. Subsequently, the
level of NRG1 type III expression on myelinated axons determines
myelin sheath thickness [78].
In the CNS, NRG1/ErbB signaling has been implicated in neuro-
nal migration and in synaptic function [79]. In studies in vitro,
NRG1 signaling also affects oligodendrocyte speciﬁcation, differen-tiation and myelination [80–82], and heterozygous NRG1 type III
mutants are hypomyelinated [83]. Oligodendrocytes and their pro-
genitors express ErbB2, ErbB3 and ErbB4, and these two receptors
have been suggested to control CNS myelination in vivo, [81].
Importantly, however, analysis conditional null mutants lacking
NRG1 with onset at different stages of neural development has re-
vealed that the CNS in these animals myelinates normally [84].
Experiments using disruption of ErbB signaling have produced
similar ﬁndings. While oligodendrocytes express ErbB2 and ErbB4
homo/heterodimers, ErbB2 lacks ligand-binding activity. However,
mice conditionally null for both ErbB3 and ErbB4 receptors myeli-
nate normally in the absence of oligodendroglial neuregulin signal-
ing [84]. Interestingly, however, transgenic overexpression of
NRG1 type I or NRG1 type III leads to signiﬁcant CNS hypermyeli-
nation [84]. Thus, collectively these data suggest that NRG1/ErbB
signaling plays different roles in myelin formation in the PNS ver-
sus the CNS. Whereas neuregulin signaling regulates oligodendro-
cyte development and central myelin formation, control of
oligodendrocyte myelination is signiﬁcantly NRG/ErbB-indepen-
dent. Thus, these ﬁndings signiﬁcantly impact the translational po-
tential for this pathway as a therapeutic avenue for myelin repair
in MS.
2.5. Retinoid X receptor signaling
Retinoid X receptors (RXRs) are nuclear receptors with impor-
tant functions in regulation of cell proliferation and differentiation
[85]. RXRa, RXRb and RXRc can form homodimers or heterodimers
with other nuclear receptors, including retinoic acid receptors, thy-
roid hormone receptors, vitamin D receptors and peroxisome pro-
liferator activator proteins, to control transcription of target genes.
Suggesting potential translational relevance, all three members of
the RXR family are highly expressed in lesions following CNS injury
[86]. Interestingly, recent work has implicated RXRs as positive
regulators of OPC differentiation [87]. Studies have shown that
RXRc is highly expressed in oligodendrocyte lineage cells during
CNS remyelination in rodents, and that in acute and remyelinating
MS lesions RXRc is highly expressed by oligodendrocyte lineage
cells, macrophages and astrocytes, but that expression is very
low in chronic inactive lesions [87]. Importantly, knockdown of
RXR-c inhibits oligodendrocyte differentiation in vitro. Moreover,
mice that lack RXR-c display efﬁcient repopulation of demyelinat-
ed lesions with OPCs, but delayed differentiation of these cells into
mature oligodendrocytes [87]. In addition, administration of the
RXR agonist 9-cis-retinoic acid to aged rats after demyelination re-
sults in an increase in remyelinated axons. Collectively, these data
implicate RXR-c as a regulator of OPC maturation and remyelina-
tion, and suggest it as a future avenue for regenerative therapy in
MS.3. Inhibitors of maturation and myelination
While committed oligodendrocyte progenitors (OPCs) have
been detected in adult human brain and remyelination has been
demonstrated in MS lesions [5,10–12], the capacity for regenera-
tion in MS appears limited [88]. The mechanisms underlying this
failure of repair are incompletely characterized [89,90]. Interest-
ingly, recent studies have suggested that remyelinating cells may
also arise from the proliferation and differentiation into mature
oligodendrocytes of neural progenitor cells (NPCs) from germina-
tive areas of the telencephalon such as the subventricular zone
(SVZ) [91,92], thus NPCs may represent an additional source of
remyelinating cells in MS. Like all progenitors, OPCs and NPCs
are subject to precisely coordinated intrinsic and extrinsic signals
that provide highly regulated control of the balance between and
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signals may facilitate expansion of the available pools of progeni-
tors, and/or their subsequent differentiation into myelin-forming
cells.
3.1. Bone morphogenetic proteins
3.1.1. Role of BMPs in oligodendrocyte development
Bone morphogenetic proteins (BMPs) are a group of soluble pro-
teins with more than 20members, representing a major subclass of
the transforming growth factor-b (TGFb) superfamily. They are
classiﬁed into ﬁve subgroups [93]. BMP ligands bind to a complex
of the BMP receptor type 2 and Type 1 (a or b), leading to phos-
phorylation of R-Smads1, 5 and 8 and triggering their translocation
to the nucleus with the co-Smad, Smad4 [94].
BMPs play pivotal roles in morphogenesis from gastrulation on-
wards [95]. For example, in the spinal cord, development of neuro-
nal populations is dependent on the relative gradients of roof
plate-derived dorsal BMPs, versus the ventralizing morphogen So-
nic hedgehog (Shh), which is expressed by the notochord and ﬂoor
plate [96,97]. The same cues later control oligodendrocyte speciﬁ-
cation and maturation. Generation of oligodendrocyte progenitor
cells (OPCs) in the spinal cord occurs in two phases [98]. The ﬁrst
is ventral, with OPCs observed initially within the ventricular zone
of the motor neuron progenitor (pMN) domain of neuroepithelium
[99]. This requires Nkx6-regulated expression of the bHLH tran-
scription factor Olig2, and occurs under the inﬂuence of Shh
[100]. Conversely, the second phase occurs dorsally [101,102],
and depends on inhibition of BMPs by the speciﬁc inhibitor Noggin
[103,104]. BMPs restrict Shh-induced oligodendrocyte speciﬁca-
tion [103,105] and the differentiation of speciﬁed cells [104,106]
(Fig. 1). Blockade of BMP signaling induces oligodendrocyte gener-
ation both in vitro and in vivo [106,107].
3.1.2. BMP expression following CNS insult
Importantly, BMP expression is also upregulated following CNS
injury or inﬂammation, and has been linked to glial scar formation
[108–110]. BMPs are also signiﬁcantly upregulated in models of
disease resulting in demyelination, suggesting relevance to myelin
repair in the adult CNS [106]. For example, both lysolethicin-in-
duced demyelination in the spinal cord and ethidium bromide
injection into the caudal cerebellar peduncle have been shown to
result in upregulation of BMP4 [111,112]. Moreover, expression
of BMPs 4, 6 and 7 is signiﬁcantly increased in the spinal cord in
EAE, correlating with disease severity [113]. BMP4 and 5 are also
both detected in MS lesions in post mortem samples [114]. Inhibi-
tion of BMP signaling has therefore been suggested as a route to
promotion of myelin repair [106]. Although still early in its trans-
lational development, such a strategy may represent a future ave-
nue for understanding and manipulating glial responses in MS
lesions.
3.2. Canonical Notch pathway
The Notch signaling pathway is an important regulator of the
balance between OPC proliferation and differentiation in the devel-
oping CNS [115,116]. The Notch family includes four cell surface
receptors (Notch1–Notch4). Following binding of the receptor to
its ligand, two cleavages, the ﬁrst mediated by an ADAM metallo-
protease and a the second by a c-secretase complex, release the
intracellular domain of the receptor (NICD) from the cell mem-
brane, and it then translocates to the nucleus where it activates
the transcription of target genes [117]. Contact-mediated activa-
tion of canonical Notch signaling by ligands including Jagged1
and Delta1 inhibits OPC differentiation and is permissive for prolif-
eration [115,116] (Fig. 1). Conversely, activation of a non-canonicalNotch signaling pathway triggered by axonal ligands including F3/
contactin has also been reported in OPC, and this pathway has been
implicated in instructive effects on maturation [118]. Interestingly,
studies have also implicated Notch signaling in maintenance of the
size of the NPC pool in the subventricular zone [119–121], suggest-
ing relevance to both progenitor populations that may generate
remyelinating cells.
Interestingly, EAE and MS lesions have been shown to display
high amounts of the Notch1 receptor and its canonical ligand Jag-
ged1, and further characterization has revealed that Jagged-1 is ex-
pressed by reactive astrocytes under inﬂammatory conditions
under the inﬂuence of the cytokine TGFb1, while Notch-1 and its
downstream effector Hes5 localize to OPCs [122,123]. Notch sig-
naling has thus been suggested to act as a regulator of the balance
between differentiation and maintenance of the progenitor pool in
demyelinating conditions. However, studies examining myelin re-
pair in vivo have reported contrasting ﬁndings. Initial experiments
using PLPCreERT2:Notch1ﬂ/ﬂ animals did not report strong effects on
remyelination [124]. Conversely, subsequent studies of lysoleci-
thin-induced demyelinating lesions in Olig1Cre:Notch112f/12f mice
revealed mildly potentiated OPC differentiation and accelerated
remyelination [125]. Further complicating the ﬁeld, it has also
been proposed that canonical Notch signaling in OPCs may be
countered in chronic MS lesions by the non-canonical pathway
[126].
3.3. Wingless (Wnt) signaling
In addition to extrinsic cues in lesions, progenitor maturation
may also be regulated by intrinsic signals. For initiation of myelina-
tion, immature progenitors must exit the cell cycle and differenti-
ate [127], and this transition has recently been shown to involve
epigenetic regulation, which can control cell type-speciﬁc tran-
scriptional states. How these factors participate to remyelination
in the lesioned CNS remains only partially understood, but studies
have reported the involvement of histone deacetylases (HDAC) in
these events [128,129]. HDAC are a class of enzymes that antago-
nize the actions of histone acetyltransferases (HAT). Acetylation
and deacetylation oppose each other, with acetylation functionally
associated with active and open chromatin, whereas deacetylation
correlates with inactive, closed chromatin [130]. Interestingly,
interactions have been demonstrated between HDAC and Wingless
(Wnt) signaling, in which canonical Wnt-mediated inhibition of
OPC maturation was reversed by HDAC1 and 2 [131]. This molec-
ular communication within OPC appears to be important for con-
trol of oligodendrocyte lineage commitment and differentiation
[132].
The transcription factor YY1 (Yin-Yang 1) is one of the mole-
cules implicated in control of the exit of OPCs from the cell cycle
[133], and can act either as a transcriptional repressor or activator.
Interestingly, conditional oligodendrocyte-speciﬁc ablation of YY1
results in impaired CNS myelination, accompanied by arrest of OPC
differentiation [133]. This block has been linked to loss of recruit-
ment of YY1 and inhibitory HDACs to the promoters of inhibitors
such as the Wnt transcription factor 4 (Tcf4), and the helix-loop-
helix factor Id4, resulting in potent restriction of OPC maturation.
Relevance of these mechanisms to myelin repair has been sug-
gested by the recent demonstration that Wnt–cateninb1 signaling
is active in oligodendrocyte lineage cells surrounding MS lesions,
and that dysregulation of Wnt signaling in OPCs results in delayed
myelin formation and repair [134,135]. Unexpectedly, however,
Tcf4-null mice display reduced rather than potentiated expression
of oligodendrocyte terminal differentiation genes [136]. Thus, the
role of Wnt signaling in myelination and remyelination, and its po-
tential as a novel translational avenue in MS, remain incompletely
understood.
3818 J. Zhang et al. / FEBS Letters 585 (2011) 3813–38204. Future directions
Approaches directly targeting progenitors of myelinating
oligodendrocytes may lead to improved long-term outcomes and
delay accumulation of chronic demyelination and perhaps axonal
transection in MS. They might be used in combination with
currently-approved immunoregulators. However, these strategies
have yet to meet with successful clinical trials in human patients,
for reasons that are not fully understood. Potential confounds in-
clude incomplete CNS access, actions on additional lineages, and
species differences. Moreover, the relationship between demyelin-
ation and axonal transection remains unclear, particularly impor-
tant since the latter is reported to underlie permanent disability
observed later in the disease course [2]. Notwithstanding these dif-
ﬁculties, protective and regenerative approaches represent an
increasingly important translational focus. Their successful devel-
opment is a critical goal for MS research.
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